OMB APPROVAL |
| OMB Number: 3235-0060 |
| Expires: April 30, 2009 |
| Estimated average burden |
| hours per response.........5.0 |
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): May 7, 2007
Molecular Pharmacology (USA) Limited
(Exact name of Registrant as specified in charter)
Nevada | 000-50156 | 71-0900799 |
(State or other jurisdiction
of incorporation) | (Commission
File Number) | (IRS Employer
Identification No.) |
| | | |
8721 Santa Monica Boulevard, Los Angeles, California | 90069-4507 |
(Address of principal executive offices) | (Zip Code) |
| | |
Registrant's telephone number, including area code: | 011-61-8-9443-3011 |
| | |
Not Applicable |
(Former name or former address if changes since last report) |
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
| [ ] | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| [ ] | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| [ ] | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| [ ] | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
This document includes "forward-looking" statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Other than statements of historical fact, all statements regarding industry prospects, the consummation of the transactions described in this document and the Company's expectations regarding the future performance of its businesses and its financial position are forward-looking statements. These forward-looking statements are subject to numerous risks and uncertainties.
1
ITEM 8.01 - OTHER EVENTS
The attached press release dated May 7, 2007, regarding the addition of two patent applications in the fields of cytokine mediating compositions and COX-2 inhibition to the company's technology portfolio. The patents are held by Cambridge Scientific Pty Ltd, a wholly owned subsidiary of the Registrant's shareholder, Pharmanet Group Limited.
ITEM 9.01 - FINANCIAL STATEMENTS AND EXHIBITS
(a) Financial Statements of Business Acquired. N/A
(b) Pro forma financial information. N/A
(c) Exhibits.
As described in Item 8.01 of this Report, the following exhibit is filed as part of this Current Report on Form 8-K:
| | | |
| Exhibit No. | | Description |
| | | |
| 99.1 | | Press Release dated May 7, 2007 |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
THE REGISTRANT
By:
/s/ Jeff Edwards
_________________________________
Jeff Edwards
President , Chief Executive Officer
and a Member of the Board of Directors
Dated: May 7, 2007
2
